Brianna Marie Lax
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Brianna Marie Lax has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Jordan A. Stinson
Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts
21 shared publications - Karl Dane Wittrup
Department of Chemical Engineering Massachusetts Institute of Technology Cambridge Massachusetts USA
21 shared publications - Allison Sheen
Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts
20 shared publications - Elizabeth Fink
Department of Chemical Engineering, Massachusetts Institute of Technology; Cambridge, MA, USA
20 shared publications - Grace N. Yang
Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts
20 shared publications - Joseph R. Palmeri
Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA
20 shared publications
Latest Publications
- Open Access
- 5 August 2026
- Published by American Chemical Society (ACS) in Chem & Bio Engineering
- Vol. 3 (10) , 865-875
Data-Efficient Distal Engineering of Fluorinase Using Zero-Shot Models
Fluorinases have high potential for industrial biofluorination, but any applications have been precluded by low catalytic efficiency and resistance to active site engineering. In this work, we employed PRIZM, a computational workflow utilizing an existing low-N data set and zero-shot models for in silico prediction of activity-enhancing mutations at distal sites. The combination of these predictions with expert opinion led to the identification of 21 fluorinase mutants with enhanced relative activities, while 3 variants showed increased melting temperatures. A mutation in the hexameric interface, K237R, resulted in the largest stability gain, a more than 3.2-fold improvement in catalytic efficiency at 57 °C, and an 8-fold increase in relative activity at 62 °C. These results highlight the potential of distal fluorinase engineering for improving properties required to realize its industrial applications.
- 5 August 2026
- Published by American Chemical Society (ACS) in Chem & Bio Engineering
- Vol. 3 (10) , 865-875
Open AccessData-Efficient Distal Engineering of Fluorinase Using Zero-Shot Models
Fluorinases have high potential for industrial biofluorination, but any applications have been precluded by low catalytic efficiency and resistance to active site engineering. In this work, we employed PRIZM, a computational workflow utilizing an existing low-N data set and zero-shot models for in silico prediction of activity-enhancing mutations at distal sites. The combination of these predictions with expert opinion led to the identification of 21 fluorinase mutants with enhanced relative activities, while 3 variants showed increased melting temperatures. A mutation in the hexameric interface, K237R, resulted in the largest stability gain, a more than 3.2-fold improvement in catalytic efficiency at 57 °C, and an 8-fold increase in relative activity at 62 °C. These results highlight the potential of distal fluorinase engineering for improving properties required to realize its industrial applications.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Tumor Integrin-Targeted Glucose Oxidase Enzyme Promotes ROS-Mediated Cell Death that Combines with Interferon Alpha Therapy for Tumor Control
Characterization of recombinant glucose oxidase fusions
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Tumor Integrin-Targeted Glucose Oxidase Enzyme Promotes ROS-Mediated Cell Death that Combines with Interferon Alpha Therapy for Tumor Control
Characterization of recombinant glucose oxidase fusions
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Tumor Integrin-Targeted Glucose Oxidase Enzyme Promotes ROS-Mediated Cell Death that Combines with Interferon Alpha Therapy for Tumor Control
Fluorescence intensities of OT-I phenotypic markers from the cross-presentation assay with IFNa
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Tumor Integrin-Targeted Glucose Oxidase Enzyme Promotes ROS-Mediated Cell Death that Combines with Interferon Alpha Therapy for Tumor Control
Fluorescence intensities of OT-I phenotypic markers from the cross-presentation assay with IFNa
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from Tumor Integrin-Targeted Glucose Oxidase Enzyme Promotes ROS-Mediated Cell Death that Combines with Interferon Alpha Therapy for Tumor Control
2.5F-GOX and MSA-IFNa do not cause toxicity in mice but fail to generate anti-tumor memory
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Tumor Integrin-Targeted Glucose Oxidase Enzyme Promotes ROS-Mediated Cell Death that Combines with Interferon Alpha Therapy for Tumor Control
2.5F-GOX and MSA-IFNa do not cause toxicity in mice but fail to generate anti-tumor memory
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Tumor Integrin-Targeted Glucose Oxidase Enzyme Promotes ROS-Mediated Cell Death that Combines with Interferon Alpha Therapy for Tumor Control
Cross-presentation assay myeloid cell gating strategy
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Tumor Integrin-Targeted Glucose Oxidase Enzyme Promotes ROS-Mediated Cell Death that Combines with Interferon Alpha Therapy for Tumor Control
Cross-presentation assay myeloid cell gating strategy
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Tumor Integrin-Targeted Glucose Oxidase Enzyme Promotes ROS-Mediated Cell Death that Combines with Interferon Alpha Therapy for Tumor Control
Cross-presentation assay T-cell gating strategy
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Tumor Integrin-Targeted Glucose Oxidase Enzyme Promotes ROS-Mediated Cell Death that Combines with Interferon Alpha Therapy for Tumor Control
Cross-presentation assay T-cell gating strategy
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Tumor Integrin-Targeted Glucose Oxidase Enzyme Promotes ROS-Mediated Cell Death that Combines with Interferon Alpha Therapy for Tumor Control
Comparison of OT-I phenotypes in cross-presentation assay after treatment with immunogenic cell stress-inducing chemotherapy
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Tumor Integrin-Targeted Glucose Oxidase Enzyme Promotes ROS-Mediated Cell Death that Combines with Interferon Alpha Therapy for Tumor Control
Comparison of OT-I phenotypes in cross-presentation assay after treatment with immunogenic cell stress-inducing chemotherapy
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Tumor Integrin-Targeted Glucose Oxidase Enzyme Promotes ROS-Mediated Cell Death that Combines with Interferon Alpha Therapy for Tumor Control
Additional flow analysis of 2.5F-GOX dose escalation study
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Tumor Integrin-Targeted Glucose Oxidase Enzyme Promotes ROS-Mediated Cell Death that Combines with Interferon Alpha Therapy for Tumor Control
Additional flow analysis of 2.5F-GOX dose escalation study
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Tumor Integrin-Targeted Glucose Oxidase Enzyme Promotes ROS-Mediated Cell Death that Combines with Interferon Alpha Therapy for Tumor Control
Bolus hydrogen peroxide is cytotoxic but rapidly cleared by cancer cells
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Tumor Integrin-Targeted Glucose Oxidase Enzyme Promotes ROS-Mediated Cell Death that Combines with Interferon Alpha Therapy for Tumor Control
Bolus hydrogen peroxide is cytotoxic but rapidly cleared by cancer cells